28399372|t|A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria
28399372|a|Drug efflux mechanisms interact synergistically with the outer membrane permeability barrier of Gram-negative bacteria, leading to intrinsic resistance that presents a major challenge for antibiotic drug development. Efflux pump inhibitors (EPIs) which block the efflux of antibiotics synergize antibiotics, but the clinical development of EPI / antibiotic combination therapy to treat multidrug-resistant (MDR) Gram-negative infections has been challenging. This is in part caused by the inefficiency of current EPIs to penetrate the outer membrane and resist efflux. We demonstrate that conjugation of a tobramycin (TOB) vector to EPIs like NMP, paroxetine, or DBP enhances synergy and efficacy of EPIs in combination with tetracycline antibiotics against MDR Gram-negative bacteria including Pseudomonas aeruginosa. Besides potentiating tetracycline antibiotics, TOB - EPI conjugates can also suppress resistance development to the tetracycline antibiotic minocycline, thereby providing a strategy to develop more effective adjuvants to rescue tetracycline antibiotics from resistance in MDR Gram-negative bacteria.
28399372	2	19	Tobramycin Vector	T103	UMLS:C0040341
28399372	29	36	Synergy	T033	UMLS:C1318081
28399372	53	75	Efflux Pump Inhibitors	T103	UMLS:C1254351
28399372	104	126	Gram-Negative Bacteria	T007	UMLS:C0018150
28399372	127	138	Drug efflux	T038	UMLS:C1512072
28399372	150	158	interact	T038	UMLS:C0687133
28399372	184	198	outer membrane	T017	UMLS:C1167331
28399372	199	211	permeability	T038	UMLS:C0007605
28399372	212	219	barrier	T038	UMLS:C0028778
28399372	223	245	Gram-negative bacteria	T007	UMLS:C0018150
28399372	258	267	intrinsic	T082	UMLS:C0205102
28399372	301	310	challenge	T058	UMLS:C0805586
28399372	315	325	antibiotic	T103	UMLS:C0003232
28399372	326	342	drug development	T062	UMLS:C1512068
28399372	344	366	Efflux pump inhibitors	T103	UMLS:C1254351
28399372	368	372	EPIs	T103	UMLS:C1254351
28399372	390	396	efflux	T038	UMLS:C1512072
28399372	400	411	antibiotics	T103	UMLS:C0003232
28399372	422	433	antibiotics	T103	UMLS:C0003232
28399372	443	463	clinical development	T062	UMLS:C1512068
28399372	467	470	EPI	T103	UMLS:C1254351
28399372	473	483	antibiotic	T103	UMLS:C0003232
28399372	484	503	combination therapy	T058	UMLS:C0013218
28399372	507	512	treat	T058	UMLS:C0087111
28399372	539	563	Gram-negative infections	T038	UMLS:C0085423
28399372	573	584	challenging	T058	UMLS:C0805586
28399372	616	628	inefficiency	T033	UMLS:C0231184
28399372	640	644	EPIs	T103	UMLS:C1254351
28399372	662	676	outer membrane	T017	UMLS:C1167331
28399372	688	694	efflux	T038	UMLS:C1512072
28399372	716	727	conjugation	T038	UMLS:C1160466
28399372	733	743	tobramycin	T103	UMLS:C0040341
28399372	745	748	TOB	T103	UMLS:C0040341
28399372	760	764	EPIs	T103	UMLS:C1254351
28399372	770	773	NMP	T103	UMLS:C0044097
28399372	775	785	paroxetine	T103	UMLS:C0070122
28399372	790	793	DBP	T201	UMLS:C0428883
28399372	803	810	synergy	T033	UMLS:C1318081
28399372	827	831	EPIs	T103	UMLS:C1254351
28399372	852	876	tetracycline antibiotics	T103	UMLS:C1744619
28399372	889	911	Gram-negative bacteria	T007	UMLS:C0018150
28399372	922	944	Pseudomonas aeruginosa	T007	UMLS:C0033809
28399372	954	966	potentiating	T038	UMLS:C2242637
28399372	967	991	tetracycline antibiotics	T103	UMLS:C1744619
28399372	993	996	TOB	T103	UMLS:C0040341
28399372	999	1002	EPI	T103	UMLS:C1254351
28399372	1062	1085	tetracycline antibiotic	T103	UMLS:C1744619
28399372	1086	1097	minocycline	T103	UMLS:C0026187
28399372	1154	1163	adjuvants	T103	UMLS:C0001552
28399372	1174	1198	tetracycline antibiotics	T103	UMLS:C1744619
28399372	1222	1244	Gram-negative bacteria	T007	UMLS:C0018150